pentapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
== Applications == CagriSema is under investigation to treat type 2 diabetes and obesity. Preliminary trial results found a greater weight loss compared to either semaglutide or cagrilintide alone. HbA1c was significantly improved compared to cagrilintide alone and non-significantly better than semaglutide alone. In a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, comparable in efficacy to tirzepatide.
== Dietary nutrition == Dietitians may recommend that minerals are best supplied by ingesting specific foods rich with the chemical element(s) of interest. The elements may be naturally present in the food (e.g., calcium in dairy milk) or added to the food (e.g., orange juice fortified with calcium; iodized salt fortified with iodine). Dietary supplements can be formulated to contain several different chemical elements (as compounds), a combination of vitamins and/or other chemical compounds, or a single element (as a compound or mixture of compounds), such as calcium (calcium carbonate, calcium citrate) or magnesium (magnesium oxide), or iron (ferrous sulfate, iron bis-glycinate). The dietary focus on chemical elements derives from an interest in supporting the biochemical reactions of metabolism with the required elemental components. Appropriate intake levels of certain chemical elements have been demonstrated to be required to maintain optimal health. Diet can meet all the body's chemical element requirements, although supplements can be used when some recommendations are not adequately met by the diet. An example would be a diet low in dairy products, and hence not meeting the recommendation for calcium.
In February 2022, Castillo held a bilateral meeting with then Brazilian president Jair Bolsonaro in Porto Velho. Although Bolsonaro, who was politically right-wing, harshly criticized Castillo's victory in 2021, after the meeting the Brazilian president assured that the differences had been overcome, that what had previously been declared had been forgotten, stating that Castillo was a defender of liberty and "conservative values", and that both countries would work to maintain a good relationship. The foreign ministries of both countries issued a joint statement agreeing to strengthen relations between both nations and reinforce the "strategic alliance".
Pralmorelin (INN; brand name GHRP Kaken 100; former developmental codes KP-102, GPA-748, and WAY-GPA-748; also known as pralmorelin hydrochloride (JAN), pralmorelin dihydrochloride (USAN), growth hormone-releasing peptide 2, and GHRP-2) is a growth hormone secretagogue (GHS) used as a diagnostic agent that is marketed by Kaken Pharmaceutical in Japan in a single-dose formulation for the assessment of growth hormone deficiency (GHD). Pralmorelin is an orally-active, synthetic peptide drug, specifically, an analogue of met-enkephalin, with the amino acid sequence D-Ala-D-(β-naphthyl)-Ala-Trp-D-Phe-Lys-NH2. It acts as a ghrelin/growth hormone secretagogue receptor (GHSR) agonist, and was the first of this class of drugs to be introduced clinically. Acute administration of the drug markedly increases the levels of plasma growth hormone (GH) and reliably induces sensations of hunger and increases food intake in humans. Pralmorelin was also under investigation for the treatment of GHD and short stature (pituitary dwarfism), and made it to phase II clinical trials for these indications, but was ultimately never marketed for them. This may be because the ability of pralmorelin to increase plasma GH levels is significantly lower in people with GHD relative to healthy individuals.
Traditional approaches in treating patients with DDD-resultant herniated discs oftentimes include discectomy—which, in essence, is a spine-related surgical procedure involving the removal of damaged intervertebral discs (either whole removal, or partially-based). The former of these two discectomy techniques involved in open discectomy is known as Subtotal Discectomy (SD; or, aggressive discectomy) and the latter, Limited Discectomy (LD; or, conservative discectomy). However, with either technique, the probability of post-operative reherniation exists and at a considerably high maximum of 21%, prompting patients to potentially undergo recurrent disk surgery. New treatments are emerging that are still in the beginning clinical trial phases. Glucosamine injections may offer pain relief for some without precluding the use of more aggressive treatment options. Adult stem cell or cell transplantation therapies for disc regeneration are in their infancy of development, but initial clinical trials have shown cell transplantation to be safe and initial observations suggest some beneficial effects for associated pain and disability. An optimal cell type, transplantation method, cell density, carrier, or patient indication remains to be determined. Investigation into mesenchymal stem cell therapy knife-less fusion of vertebrae in the United States began in 2006 and a DiscGenics nucleus pulposus progenitor cell transplantation clinical trial has started as of 2018 in the United States and Japan.
Sources: en.wikipedia.org
During preparation for the Fram expedition to the North Pole in 1893–1896, 33 dogs were purchased from the Nenets people. Of these dogs, 28 were used in an attempt on the North Pole; none of those survived. The remaining dogs, including pups born during the voyage, were left aboard the ship. In April 1893 the bitch had another litter, most of them white. According to Nansen's notes "all the dogs were strong, tough and excellent at pulling sleds; they worked very well in hunting Polar bears [as well]." These dogs would become the original Samoyeds. British Zoologist Ernest Kilburn-Scott is widely considered the founder of Samoyed breed. In 1889, he returned to England with a puppy he had purchased from a Samoyed encampment near Arkhangelsk. In the early days, imported dogs were a wide array of colors. However, it was widely believed that the "true Samoyeds", as originally bred in Siberia, were predominantly white. In 1909, the first official breed standard for the Samoyed was developed in England. In 1898–1900, Carsten Borchgrevink brought 90 Samoyeds to the southern hemisphere during the Southern Cross Expedition. In his book To the South Polar Regions, expedition member Louis Bernacchi wrote:
== Post-band projects == Masters continues to create music, often of an experimental nature. His first project after Pale Saints was Spoonfed Hybrid with former A.C. Temple member Chris Trout. They released their self-titled debut album in 1993 and their second album, Hibernation Shock, in 1996. In 1994, Masters, recording under the name Pail Saint, released the album Noise Bucket on Time Stereo, the label run by His Name Is Alive auteur Warren Defever. Masters and Defever then teamed up and began to release music as ESP Summer. In autumn 1998, Masters released a 7-inch EP under the name Friendly Science Orchestra entitled Miniature Album, which became an NME 'Single of the Week'. As of 2005, Masters lived in Japan. His projects, including Wingdisk with Mark Tranmer of Gnac and the Montgolfier Brothers, can be viewed on his website, The Institute of Spoons. Naysmith and Cooper formed Lorimer, and later continued working together in the Leeds band the Terminals. The band released a single in December 2006, entitled "Dictator", on Double Dragon Records. The band changed their name again to Cyanide Pills and by 2011 had released five singles and one album on Damaged Goods Records. Naysmith and Cooper worked on a new project of atmospheric instrumental music under the name The Program. Naysmith soon formed the X-Rays Eyes alongside Cooper's bandmate Sy Shields. Naysmith died on 4 April 2024. Barham has gone on to record melodic electronica under the name Kuchen.
== Production and composition == Dalbavancin is manufactured by fermentation of a selected Nonomuraea strain to generate the natural glycopeptide complex A-40926. This precursor is then selectively esterified at the carboxyl group of its sugar moiety, its peptidyl carboxyl group is amidated and the ester of the N-acylaminoglucuronic acid carboxyl group is saponified. The outcome is a compound mixture of two closely related structural families—A and B—that can be further subdivided into a total of five subtypes (see table below). At least ten different dalbavancin components have been described, of which the B0 component makes up around 80–98 wt%.
{\displaystyle Q={\begin{pmatrix}{-(x_{1}+x_{2}+x_{3})}&x_{1}&x_{2}&x_{3}\\{\pi _{1}x_{1} \over \pi _{2}}&{-({\pi _{1}x_{1} \over \pi _{2}}+x_{4}+x_{5})}&x_{4}&x_{5}\\{\pi _{1}x_{2} \over \pi _{3}}&{\pi _{2}x_{4} \over \pi _{3}}&{-({\pi _{1}x_{2} \over \pi _{3}}+{\pi _{2}x_{4} \over \pi _{3}}+x_{6})}&x_{6}\\{\pi _{1}x_{3} \over \pi _{4}}&{\pi _{2}x_{5} \over \pi _{4}}&{\pi _{3}x_{6} \over \pi _{4}}&{-({\pi _{1}x_{3} \over \pi _{4}}+{\pi _{2}x_{5} \over \pi _{4}}+{\pi _{3}x_{6} \over \pi _{4}})}\end{pmatrix}}}
== Other uses == Opus (mythology), a son of Zeus Opus, Greece, a city in ancient Locris, Greece Opus (Elis), a town in ancient Elis, Greece Opus (architecture), generic term for "construction method", "construction material", "masonry", in use in Ancient Rome OPUS (chromatography), a line of chromatography columns manufactured by Repligen Corporation OPUS (psychiatry), a Danish early intervention program for people with schizophrenia spectrum disorders Opus Film, a Polish film production company
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
It is a synthetic pentapeptide in the growth hormone secretagogue family. The chain contains five residues, two of which are non-natural amino acids.